{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:52:34Z","timestamp":1791924754133,"version":"4.3.4"},"reference-count":10,"publisher":"BMJ","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40425-018-0318-x","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T13:09:32Z","timestamp":1517317772000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Inflammatory demyelinating polyneuropathy versus leptomeningeal disease following Ipilimumab"],"prefix":"10.1136","volume":"6","author":[{"given":"Lorraine","family":"Cafuir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nilesh","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Kesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Voloschin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"318_CR1","doi-asserted-by":"publisher","first-page":"S265","DOI":"10.4103\/2152-7806.111304","volume":"4","author":"E Le Rhun","year":"2013","unstructured":"Le Rhun E, Taillibert S, Chamberlain MC. Carcinomatous meningitis: Leptomeningeal metastases in solid tumors. Surg Neurol Int. 2013;4:S265\u201388.","journal-title":"Surg Neurol Int"},{"key":"318_CR2","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s40425-016-0148-7","volume":"4","author":"A Amin","year":"2016","unstructured":"Amin A, Lawson DH, Salama AK, Koon HB, Guthrie T Jr, Thomas SS, O'Day SJ, Shaheen MF, Zhang B, Francis S, Hodi FS. Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma. J Immunother Cancer. 2016;4:44.","journal-title":"J Immunother Cancer"},{"key":"318_CR3","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1017\/S0317167100015080","volume":"40","author":"AM Chau","year":"2013","unstructured":"Chau AM, Yu A, Keezer MR. Chronic inflammatory demyelinating polyneuropathy and metastatic melanoma. Can J Neurol Sci. 2013;40:750\u20132.","journal-title":"Can J Neurol Sci"},{"key":"318_CR4","first-page":"167","volume":"17","author":"MB Dbouk","year":"2012","unstructured":"Dbouk MB, Nafissi S, Ghorbani A. Chronic inflammatory demyelinating polyneuropathy following malignant melanoma. Neurosciences (Riyadh). 2012;17:167\u201370.","journal-title":"Neurosciences (Riyadh)"},{"key":"318_CR5","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/j.1471-4159.1986.tb00795.x","volume":"47","author":"AB Noronha","year":"1986","unstructured":"Noronha AB, Harper JR, Ilyas AA, Reisfeld RA, Quarles RH. Myelin-associated glycoprotein shares an antigenic determinant with a glycoprotein of human melanoma cells. J Neurochem. 1986;47:1558\u201365.","journal-title":"J Neurochem"},{"key":"318_CR6","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1007\/s10637-011-9787-1","volume":"30","author":"F Bompaire","year":"2012","unstructured":"Bompaire F, Mateus C, Taillia H, De Greslan T, Lahutte M, Sallansonnet-Froment M, Ouologuem M, Renard JL, Gorochov G, Robert C, Ricard D. Severe meningo-radiculo-neuritis associated with ipilimumab. Investig New Drugs. 2012;30:2407\u201310.","journal-title":"Investig New Drugs"},{"key":"318_CR7","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/neuonc\/nou001","volume":"16","author":"B Liao","year":"2014","unstructured":"Liao B, Shroff S, Kamiya-Matsuoka C, Tummala S. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro-Oncology. 2014;16:589\u201393.","journal-title":"Neuro-Oncology"},{"key":"318_CR8","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/mus.23830","volume":"48","author":"G Manousakis","year":"2013","unstructured":"Manousakis G, Koch J, Sommerville RB, El-Dokla A, Harms MB, Al-Lozi MT, Schmidt RE, Pestronk A. Multifocal radiculoneuropathy during ipilimumab treatment of melanoma. Muscle Nerve. 2013;48:440\u20134.","journal-title":"Muscle Nerve"},{"key":"318_CR9","doi-asserted-by":"publisher","first-page":"B21","DOI":"10.1111\/j.1440-1673.2007.01793.x","volume":"51","author":"HA Kale","year":"2007","unstructured":"Kale HA, Sklar E. Magnetic resonance imaging findings in chronic inflammatory demyelinating polyneuropathy with intracranial findings and enhancing, thickened cranial and spinal nerves. Australas Radiol. 2007;51:B21\u20134.","journal-title":"Australas Radiol"},{"key":"318_CR10","doi-asserted-by":"publisher","unstructured":"Allen JA, Ney J, Lewis RA. Electrodiagnostic errors contribute to chronic inflammatory demyelinating polyneuropathy misdiagnosis. Muscle Nerve. 2017. [Epub ahead of print]. \n                    https:\/\/doi.org\/10.1002\/mus.25997\n                    \n                  .","DOI":"10.1002\/mus.25997"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-018-0318-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:43:03Z","timestamp":1601055783000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-018-0318-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["318"],"URL":"https:\/\/doi.org\/10.1186\/s40425-018-0318-x","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]},"assertion":[{"value":"7 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable, not a clinical trial.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not required by our local IRB if patient is deceased.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"DL participates in pharmaceutical trials sponsored by Bristol-Myers Squibb, the maker of Ipilimumab. VK is the Principal Investigator for the NN103 Myasthenia Gravis Study funded by the NIH. LC, ND, and AV declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"11"}}